Global Health Limited boosted customer receipts by 12.6% to A$9.53 million for FY26, completing its SaaS platform upgrade and cutting cash burn by 30%. The company targets sustained EBITDA profitability and international expansion in FY27.
- 12.6% increase in customer receipts to A$9.53 million
- 30% reduction in operating and investing cash outflows
- SaaS transition completed with 31.2% recurring revenue
- AI adoption delivers $500K in expected expense savings
- Positive cash-basis EBITDA achieved in recent quarters
Revenue Growth and Cash Flow Improvement
Global Health Limited (ASX:GLH) reported a 12.6% increase in customer receipts over the 12 months to June 2026, reaching A$9.53 million compared to A$8.46 million the previous year. This growth coincides with a 30% reduction in operating and investing cash outflows to A$812,000, reflecting tighter cost control and efficiency gains.
Cash flow improvements were driven largely by the company’s adoption of AI across key departments, enabling staff and contractor reductions and streamlining operations from sales through to support. Despite redeeming A$100,000 of Convertible Notes during the period, Global Health maintained positive cash flow momentum.
SaaS Transition Completes with Recurring Revenue Gains
The company finalized a significant technology upgrade, consolidating three on-premises applications into a single multi-tenant SaaS platform. This transition is now market ready, with recurring SaaS revenue representing 31.2% of total annual recurring revenue (ARR), up from 27.8% in FY25. The integration of the Heidi Scribe AI Platform and enhancements to patient portals and secure messaging platforms have also been completed and released.
During the quarter, Global Health deployed its MasterCare Plus Case Management SaaS to five new sites and upgraded three existing customers from legacy systems. Additional platform releases included Theatre Management and Bed Flow productivity tools tailored for hospital operations.
AI-Driven Productivity and Cost Reductions
Looking ahead, Global Health expects AI-driven productivity gains to yield an additional A$500,000 in expense savings in FY27. The company has also reduced its R&D budget by approximately A$700,000 to A$1.1 million following the completion of major development work. These savings underpin the company’s goal of maintaining EBITDA profitability and positive cash flow from FY27 onwards, having already achieved positive cash-basis EBITDA in both the March and June quarters.
Convertible Notes and Financing Strategy
Global Health is evaluating options for its Convertible Notes, which mature in June and July 2027. Potential strategies include repaying the notes from free cash flow or refinancing with lower-cost non-convertible debt. The company’s total financing facilities amount to A$2.03 million, with no unused credit lines available at quarter end.
International Expansion and Market Outlook
With the SaaS platform suite now launched after nearly A$10 million invested over four years, Global Health plans to shift focus towards scaling revenue domestically and internationally. The company aims to leverage AI-driven innovations and low-touch onboarding to tap into global healthcare markets, responding to cost pressures and staffing challenges faced by providers in Australia and abroad.
This strategic pivot aligns with broader trends in healthcare digitisation and AI adoption, positioning Global Health to capitalise on growing demand for efficient, cloud-based clinical software solutions.
Bottom Line?
Global Health’s SaaS transition and AI integration have set a foundation for scaling revenue and sustaining profitability, but execution on international expansion and debt management will be critical next steps.
Questions in the middle?
- How effectively can Global Health convert international interest into recurring SaaS revenue?
- What refinancing strategy will the company adopt for its maturing Convertible Notes?
- Will AI-driven cost savings continue to offset competitive pressures in healthcare software?